Article Sidebar

pdf
Date Published: 10/06/2024
Abstract Views: 101
Views pdf: 58
DOI: https://doi.org/10.51298/vmj.v539i2.9785
Issue
Vol. 539 No. 2 (2024)
Section
Các bài báo
How to Cite
Trịnh , N. H. G., Nghiêm, T. M. C., Nguyễn, X. A., Đặng, Q. V., & La, V. T. (2024). EVALUATION OF TREATMENT RESULTS WITH THE BEVACIZUMAB – mFOLFOX6 REGIMEN IN FIRST-LINE TREATMENT FOR STAGE IV COLORECTAL CANCER PATIENTS. Vietnam Medical Journal, 539(2). https://doi.org/10.51298/vmj.v539i2.9785

EVALUATION OF TREATMENT RESULTS WITH THE BEVACIZUMAB – mFOLFOX6 REGIMEN IN FIRST-LINE TREATMENT FOR STAGE IV COLORECTAL CANCER PATIENTS

Nguyễn Hương Giang Trịnh , Thị Minh Châu Nghiêm, Xuân Anh Nguyễn, Quang Vinh Đặng, Vân Trường La

Main Article Content

Abstract

Objectives: To evaluate the results and the side - effects of the Bevacizumab – mFOLFOX6 regimen in the first-line treatment of stage IV colorectal cancer (CRC) patients. Objects and methods: Retrospective and prospective description with longitudinal follow-up of 41 stage IV colorectal cancer patients according to AJCC 8th who were first - line treated with Bevacizumab – mFOLFOX6 regimen at Military 103 hospital and Central Military Hospital 108 from May 2019 to December 2023. Results: The median progression-free survival (PFS) was 11 months. The side-effects were generally at grades 1-2. Conclusion: The Bevacizumab – mFOLFOX6 regimen in metastatic colorectal cancer treatment was highly effective with manageable side-effects.

Article Details

Keywords

Bevacizumab, mFOLFOX6, colorectal, cancer

References

1. Sung, Ferlay, Siegel, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
2. Ibrahim, Hirschfeld, Cohen, et al. FDA drug approval summaries: oxaliplatin. Oncologist. 2004;9(1):8-12.
3. Saltz, Clarke, Díaz-Rubio, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013-2019.
4. Emmanouilides, Sfakiotaki, Androulakis, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91.
5. Stathopoulos, Batziou, Trafalis, et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology. 2010;78(5-6):376-381.
6. Hochster, Hart, Ramanathan, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26(21):3523-3529.
7. Cassidy, Clarke, Díaz-Rubio, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. 2011;105(1):58-64.
8. Berretta, Cappellani, Fiorica, et al. FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: a prospective study. Arch Gerontol Geriatr. 2011;52(1):89-93.
9. Ducreux, Bennouna, Hebbar, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer. 2011;128(3):682-690.